Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK announces first EU authorisation for Prepandrix

GSK announces first EU authorisation for Prepandrix

20th May 2008

GlaxoSmithKline (GSK) has announced that the European Commission has granted marketing authorisation for Preprandrix, its H5N1 adjuvanted pre-pandemic vaccine in all EU member states.

The firm is the first to obtain a European licence for such a vaccine, which are produced in advance of a pandemic.

It is based on the currently circulating avian H5N1 influenza virus likely to cause a pandemic and can raise immune protection against potential drift strains of the virus.

The vaccine is formulated with the company’s proprietary adjuvant system which aims to achieve a high response rate from those immunised with a low antigen dose that is active against a wide range of strains of the virus and is long lasting.

Jean-Pierre Garnier, chief executive officer of GSK, said: “This vaccine marks a significant step in the world?s ability to cope with an influenza pandemic.”

He added that the vaccine is a testament to scientists at the firm who have led the way in pre-pandemic vaccination underlying the firm’s dedication to doing what it can to prevent the effects of a pandemic and avoiding a potential public health crisis.

Last week, GSK welcomed a recommendation published in online journal Nature that stores of Tamiflu from Roche should be accompanied by additional antivirals.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.